Quanterix

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Quanterix reports strong Q4 revenue, eyes growth in neurology diagnostics

Quanterix's Q4 performance showcased revenue growth and margin improvement, underpinned by advancements in assay manufacturing and the launch of new tests. The company faces challenges in revenue management and cost control but has opportunities to drive growth through core products and competitive positioning in neurology diagnostics.

Quanterix reports robust Q1 earnings, eyes neuro research growth

Quanterix delivered strong Q1 results with revenue growth and margin improvements, while facing challenges in cash management and meeting revised guidance targets.
The company's focus on neuro research and clinical applications, along with its transformation plan, positions it well for future growth and market leadership.
Analyst inquiries highlighted areas for improvement and clarity, signaling the need for continued strategic communication and operational enhancements.

Quanterix reports robust Q2 earnings, eyes growth in diagnostics market

Quanterix's Q2 performance reflects strong revenue growth and improved profitability.
The company's focus on innovative diagnostics for Alzheimer's and neurological therapies positions it well for future growth.
Despite challenges in leadership transition and addressing specific patient needs, Quanterix remains optimistic about market adoption of blood biomarkers.

Quanterix reports strong Q3 revenue growth and advances in Alzheimer's diagnostics

Quanterix's Q3 performance reflects revenue growth, improved gross margins, and strategic collaborations in blood biomarker testing for Alzheimer's disease.
The company's strengths in expanding platform access, operational efficiency, and multimarker approaches present growth opportunities in diagnostics.
Challenges include meeting revenue growth expectations, maintaining high sensitivity levels in diagnostics, and balancing margin improvements with investments.
Opportunities exist in leveraging partnerships, developing innovative biomarker solutions, and capitalizing on the demand for comprehensive diagnostic tools in healthcare.

Quanterix reports record revenue in Q4 2023, eyes Alzheimer's diagnostics

Quanterix's Q4 2023 performance reflects strong revenue growth, improved margins, and strategic focus on innovation and market expansion.
While challenges in capital allocation and sustaining growth persist, the company's opportunities in menu expansion and Alzheimer's diagnostics are promising.
Overall, Quanterix's financial outlook for 2024 appears positive, with a clear roadmap for growth and continued market penetration.

Quanterix reports revenue growth and innovation drive amidst competition challenges

Quanterix's Q1 2024 performance reflects revenue growth, margin improvement, and innovation in disease detection assays, positioning the company for future success.
Strategic strengths include strong gross margins, successful product launches, and growth in Accelerator Lab services, driving revenue and market presence.
Challenges include competition assessment, margin maintenance, and regulatory milestones, while opportunities exist in innovation, revenue growth, and profitability focus.

Quanterix reports robust Q3 earnings, eyes growth in Alzheimer's diagnostics

Quanterix's strong revenue growth, focus on innovation, and strategic priorities position the company for continued success in the diagnostics market.
While facing challenges in maintaining gross margins and navigating regulatory landscapes, Quanterix has opportunities to drive growth through advanced diagnostics and market expansion.
By balancing customer mix, expanding menu offerings, and investing in new technologies, Quanterix is poised to capitalize on the growing demand for precision medicine and Alzheimer's disease testing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Simoa® technology has been used in research studies to detect the SARS-CoV-2 virus in serum/plasma, dried blood microsamples (DBS) and saliva samples obtained from polymerase chain reaction (PCR)+ COVID-19 patients. Published in Nature Communications, the research study of these technologies offers further evidence t

Quanterix' Simoa Technology Demonstrates Advancements in COVID-19 Research through Viral Antigen Measurements in Blood and Saliva Samples

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology and various blood-based neurology biomarker assays were used by leading research teams to power 30 total oral and poster presentations at this year's AD/PD 2021. The research efforts further underscore the vast utility of several blood-based biomarkers offered through Quanterix' Neuro

Quanterix' Simoa Technology Accelerates Critical Plasma Biomarker Research Presented at the 15th International Conference on Parkinson's & Alzheimer's Disease (AD/PDTM 2021)

PerkinElmer

Since going public just over three years ago, Quanterix Corp. (NASDAQ:QTRX) shares have quadrupled to about $63. Recently, the Billerica, Massachusetts-based diagnostics company closed another public offering, this one for 4.1 million shares at $70 a share.

Quanterix Shares Have Quadrupled Since IPO in Late 2017

Quanterix Corporation (QTRX) CEO Kevin Hrusovsky on Q4 2020 Results - Earnings Call Transcript

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the fourth quarter and 12 months ended December 31, 2020. “Responding to the pandemic crisis as well as advances in therapies to treat Alzheimer's has accelerated our leadership of precision health and the proteomics revolution,” said Chairman, Chief Executive Officer and President, Quanterix, Kevin Hru

Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2020

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman, Chief Executive Officer and President, Kevin Hrusovsky, will be delivering a virtual presentation at the Cowen 41st Annual Health Care Conference on Wednesday, March 3, at 11:00 a.m. EST. Attendees can access the public webcast at https://wsw.com/webcast/cowen81/qtrx/2002443 or by visiting the News & Events

Quanterix' Kevin Hrusovsky to Present at the Cowen 41st Annual Health Care Conference on March 3 and Appear on the Feb. 26 Episode of the Health Care Rounds Podcast

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for fourth quarter and full year 2020 after the close of trading on Tuesday, March 2, 2021. Company management will host a conference call at 4:30 p.m., ET to discuss Quanterix' financial results and provide a business update. The call will be hosted by Kevin Hrusovsky, Chairman, Ch

Quanterix Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman, Chief Executive Officer and President, Kevin Hrusovsky, will be presenting at the 10th Annual SVB Leerink Global Healthcare Conference, being held virtually from February 22 – 26, 2021. Hrusovsky's presentation will take place on Friday, February 26, at 9:20 a.m. EST. Attendees can access the public webcast at

Quanterix to Present at the 10th Annual SVB Leerink Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into an agreement to open a joint Simoa laboratory with WuXi AppTec to improve access to Quanterix' industry leading biomarker testing and development offerings across China and the APAC market. The Simoa® Joint Lab is the strategic partnership between the two companies and will be established at WuXi AppTec's

Quanterix Announces Simoa® Joint Laboratory with WuXi AppTec

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the closing of its previously announced underwritten public offering of 4,107,142 shares of its common stock at a public offering price of $70.00 per share, including 535,714 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares. Gross proceeds from the sale of the shares, before

Quanterix Announces Closing of Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the pricing of its previously announced underwritten public offering of 3,571,428 shares of its common stock at a public offering price of $70.00 per share. All of the shares in the offering will be sold by Quanterix. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offe

Quanterix Prices Public Offering of Common Stock

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it has commenced an underwritten public offering of $200.0 million of its common stock. In connection with the offering, Quanterix intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price less the underwriting discounts and commissio

Quanterix Announces Proposed Public Offering of $200.0 Million of its Common Stock

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President of Quanterix, and Founder, Powering Precision Health, Kevin Hrusovsky will present at PMWC 2021 COVID-19 Conference being held Jan. 25-27, 2021. The conference will focus on healthcare challenges and developments brought forth by the COVID-19 pandemic and will address the finan

Quanterix to Participate in PMWC 2021 COVID-19 Conference

Shares of Quanterix Corp. rallied nearly 10% in the extended session Monday after the life-sciences company said the Food and Drug Administration has issued an emergency use authorization for the company's SARS-CoV-2 antigen test. The test is intended for use with nasopharyngeal samples in people suspected of being ill with COVID-19, the company said.

Quanterix stock jumps nearly 10% after company gets EUA for COVID-19 test

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its Simoa® SARS-CoV-2 N Protein Antigen Test that can be run on the Simoa HD-X Analyzer®, a fully automated high-throughput immunoassay instrument. The Simoa SARS-CoV-2 N Protein Antigen Test detects the presence of the SARS-CoV-2

Quanterix Receives FDA Emergency Use Authorization for SARS-CoV-2 N Protein Antigen Test

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Chairman, Chief Executive Officer and President, and Founder of Powering Precision Health (PPH), Kevin Hrusovsky, will be presenting on the Company's growth and vision for the fifth consecutive year at the 39th Annual J.P. Morgan Healthcare Conference, taking place virtually. Hrusovsky's session will take place on W

Quanterix Corporation to Present At 39th Annual J.P. Morgan Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its Simoa® Semi-Quantitative SARS-CoV-2 IgG Antibody Test that can be run on the Simoa HD-X Analyzer®, a fully automated high-throughput immunoassay instrument. The Simoa Semi-Quantitative SARS-CoV-2 antibody test targets antibodi

Quanterix Receives FDA Emergency Use Authorization for Semi-Quantitative Antibody Test

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Appoints William Geist as Chief Operating Officer

 Quanterix Appoints William Geist as Chief Operating Officer

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman, Chief Executive Officer and President, Kevin Hrusovsky will participate in a virtual fireside chat discussion at the Canaccord Medical Technologies and Diagnostics Forum on November 19 at 10:30 a.m., EST. Hrusovsky will also host virtual one-on-one and group meetings with institutional investors that day. A live we

Quanterix to Participate in the Canaccord Medical Technologies and Diagnostics Forum

Quanterix Corporation's (QTRX) CEO Kevin Hrusovsky on Q3 2020 Results - Earnings Call Transcript

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its Chairman, Chief Executive Officer and President and Founder, Powering Precision Health (PPH), Kevin Hrusovsky, will speak today at the Precision Medicine Leaders Summit's (PMLS) Precision Oncology Conference. Hrusovsky's keynote presentation, “Revolutionizing Cancer Treatment and Detection with Biomarkers,” will tak

Kevin Hrusovsky to Speak at Precision Medicine Leaders Summit's Precision Oncology Conference

Quanterix: Still Bullish But Valuation Less Compelling

Abbott Labs

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a non-exclusive royalty-bearing license agreement with Abbott Laboratories (NYSE: ABT), the global healthcare company. The non-exclusive license grants Abbott access to Quanterix’ portfolio of bead-based technology patents for use in in vitro diagnostic (IVD) applications. Under the terms of the agreement

Quanterix Enters into a License Agreement that Grants Abbott Access to Portfolio of Bead-Based Technology Patents for Use in In Vitro Diagnostics

Quanterix's industry leading platform, which is highly levered to the growth in precision medicine, can detect protein biomarkers at significantly lower concentrations and at higher sensitivity vs competitors.

Quanterix: The Illumina Of Proteomics - Life Science Tools Play At A Reasonable Valuation

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced the closing of its previously announced underwritten public offering of 3,048,774 shares of its common stock at a public offering price of $32.00 per share, including 397,666 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares.

News for Quanterix Stock (QTRX)